📣 VC round data is live. Check it out!
- Public Comps
- Medtronic
Medtronic Valuation Multiples
Discover revenue and EBITDA valuation multiples for Medtronic and similar public comparables like Danaher, Stryker, Boston Scientific, Abbott and more.
Medtronic Overview
About Medtronic
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
Founded
1949
HQ

Employees
95.0K
Website
Financials (LTM)
EV
$119B
Valuation Multiples
Start free trialMedtronic Financials
Medtronic reported last 12-month revenue of $36B and EBITDA of $10B.
In the same LTM period, Medtronic generated $24B in gross profit, $10B in EBITDA, and $7B in net income.
Revenue (LTM)
Medtronic P&L
In the most recent fiscal year, Medtronic reported revenue of $34B and EBITDA of $10B.
Medtronic is profitable as of last fiscal year, with gross margin of 65%, EBITDA margin of 29%, and net margin of 21%.
Financial data powered by Morningstar, Inc.
Medtronic Stock Performance
Medtronic has current market cap of $99B, and enterprise value of $119B.
Market Cap Evolution
Medtronic's stock price is $76.97.
Medtronic share price decreased by 4.9% in the last 30 days, and by 7.2% in the last year.
Medtronic has an EPS (earnings per share) of $5.51.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $119B | $99B | 1.0% | -4.9% | -21.2% | -7.2% | $5.51 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMedtronic Valuation Multiples
Medtronic trades at 3.3x EV/Revenue multiple, and 11.6x EV/EBITDA.
EV / Revenue (LTM)
Medtronic Financial Valuation Multiples
As of May 15, 2026, Medtronic has market cap of $99B and EV of $119B.
Medtronic has a P/E ratio of 13.8x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Medtronic Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Medtronic Margins & Growth Rates
Medtronic grew revenue by 8% and EBITDA by 5% in the last fiscal year.
In the most recent fiscal year, Medtronic reported gross margin of 65%, EBITDA margin of 29%, and net margin of 21%.
Medtronic Margins
Medtronic Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Medtronic Operational KPIs
Medtronic's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Medtronic's Rule of 40 is 35% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Medtronic's Rule of X is 45% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Medtronic Competitors
Medtronic competitors include Danaher, Stryker, Boston Scientific, Abbott, Edwards Lifesciences, Intuitive Surgical, Siemens Healthineers, IDEXX Laboratories, Waters and Agilent.
Most Medtronic public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 5.3x | 5.2x | 16.8x | 16.4x | |||
| 5.1x | 5.0x | 17.9x | 17.4x | |||
| 4.4x | 4.3x | 14.3x | 13.8x | |||
| 3.9x | 3.7x | 14.5x | 14.2x | |||
| 7.2x | 6.9x | 24.2x | 22.8x | |||
| 14.6x | 13.8x | 33.7x | 31.4x | |||
| 1.5x | 1.5x | 7.8x | 7.8x | |||
| 10.0x | 9.6x | 28.5x | 27.3x | |||
This data is available for Pro users. Sign up to see all Medtronic competitors and their valuation data. Start Free Trial | ||||||
Medtronic M&A Activity
Medtronic has acquired 39 companies to date.
Last acquisition by Medtronic was on March 9th 2026. Medtronic acquired Scientia Vascular for $550M (EV/Revenue multiple of ).
Latest Acquisitions by Medtronic
| Description | Scientia Vascular is a medical device company designing neurovascular access tools for interventional procedures. Products include guide catheters, microcatheters, and wires engineered for tortuous anatomy in stroke treatment and aneurysm coiling. Utah-based since 2013, the firm prioritizes precision shapes and trackability to improve outcomes in minimally invasive endovascular therapies. Devices reach specialists in North America and Europe through distribution networks. | Fortimedix is an Enschede-based manufacturer of precision endovascular stents and delivery systems for cardiovascular interventions. Established over 15 years ago, the company provides in-house design, prototyping, and production capabilities using advanced nitinol processing and laser micromachining technologies. Acquired by OrbusNeich in 2021, Fortimedix supports medical device companies worldwide with custom stent solutions for peripheral and coronary artery treatments. | CathWorks is an Israeli medtech firm focused on computational cardiology tools for PCI optimization. Its FFRangio platform transforms standard coronary angiograms into functional assessments using AI-driven analysis, providing physicians with quantitative blood flow data to guide stent placement decisions. | Affera is a Herzliya, Israel-headquartered medical technology company. It develops the Affera X Platform, an integrated system for cardiac ablation mapping and therapy in arrhythmia treatment. The FDA-cleared technology combines high-density mapping catheters with pulsed field and radiofrequency energy sources, addressing atrial fibrillation in over 100,000 procedures annually worldwide. Partnerships with Boston Scientific expand its global reach in electrophysiology markets. | |
| HQ Country | |||||
| HQ City | Salt Lake City, UT | Heerlen | Kfar Saba | Boston, MA | |
| Deal Date | 9 Mar 2026 | 21 Nov 2024 | 12 Jul 2022 | 10 Jan 2022 | |
| Valuation | $550M | undisclosed | $585M | $925M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Medtronic acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Medtronic Investment Activity
Medtronic has invested in 25 companies to date.
Latest investment by Medtronic was on April 19th 2026. Medtronic invested in Pulnovo Medical in their $100M Series D round (EV/Revenue multiple of ).
Latest Investments by Medtronic
| Description | Pulnovo Medical is a Chinese medtech firm pioneering radiofrequency ablation catheters for pulmonary hypertension treatment. Its flagship DragonFly system received China NMPA approval in 2021 and CE Mark for European markets. Established in 2013 and headquartered in Wuxi, Jiangsu Province, the company holds global patents for its endovascular RF technology and expands into atrial fibrillation ablation devices. | Avation Medical is a wearable neuromodulation company developing patient-controlled nerve stimulation devices for chronic pain and neurological conditions. Headquartered in the United States, its platforms integrate smart sensors and apps for personalized therapy dosing. The firm advances FDA-cleared bioelectronic medicines through clinical trials in Minneapolis. | FIRE1 is a Dublin, Ireland-headquartered medical device developer focused on therapeutics for cardiovascular diseases. The company advances the FIRE1 Circulatory Support System, a percutaneous heart pump for high-risk percutaneous coronary interventions. Clinical trials conducted at centers in Europe target cardiogenic shock patients, with CE Mark pursuit underway. | CathWorks is an Israeli medtech firm focused on computational cardiology tools for PCI optimization. Its FFRangio platform transforms standard coronary angiograms into functional assessments using AI-driven analysis, providing physicians with quantitative blood flow data to guide stent placement decisions. | |
| HQ Country | |||||
| HQ City | Wuxi | Columbus, OH | Dublin | Kfar Saba | |
| Deal Date | 19 Apr 2026 | 1 Feb 2024 | 15 Mar 2023 | 12 Jul 2022 | |
| Round | Series D | Series C | Undisclosed stage | Strategic investment | |
| Raised | $100M | $22M | $25M | $75M | |
| Investors | EQT; Gaorong Capital; HSG; Lilly Asia Ventures; Medtronic; OrbiMed; Qiming Venture Partners | Angelini Ventures; Arboretum Ventures; Asahi Kasei; Avestria Ventures; JobsOhio; Medtronic; Shangbay Capital; Tonkawa Investments | Andera Partners; Gilde Healthcare; GIMV; Ireland Strategic Investment Fund; Lightstone Ventures; Medtronic; New Enterprise Associates; Novo Holdings; Seventure Partners | Medtronic | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Medtronic investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Medtronic
| When was Medtronic founded? | Medtronic was founded in 1949. |
| Where is Medtronic headquartered? | Medtronic is headquartered in United States. |
| How many employees does Medtronic have? | As of today, Medtronic has over 95K employees. |
| Who is the CEO of Medtronic? | Medtronic's CEO is Que Thanh Dallara. |
| Is Medtronic publicly listed? | Yes, Medtronic is a public company listed on NYSE. |
| What is the stock symbol of Medtronic? | Medtronic trades under MDT ticker. |
| When did Medtronic go public? | Medtronic went public in 1972. |
| Who are competitors of Medtronic? | Medtronic main competitors include Danaher, Stryker, Boston Scientific, Abbott, Edwards Lifesciences, Intuitive Surgical, Siemens Healthineers, IDEXX Laboratories, Waters, Agilent. |
| What is the current market cap of Medtronic? | Medtronic's current market cap is $99B. |
| What is the current revenue of Medtronic? | Medtronic's last 12 months revenue is $36B. |
| What is the current revenue growth of Medtronic? | Medtronic revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Medtronic? | Current revenue multiple of Medtronic is 3.3x. |
| Is Medtronic profitable? | Yes, Medtronic is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Medtronic? | Medtronic's last 12 months EBITDA is $10B. |
| What is Medtronic's EBITDA margin? | Medtronic's last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Medtronic? | Current EBITDA multiple of Medtronic is 11.6x. |
| What is the current FCF of Medtronic? | Medtronic's last 12 months FCF is $6B. |
| What is Medtronic's FCF margin? | Medtronic's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of Medtronic? | Current FCF multiple of Medtronic is 20.2x. |
| How many companies Medtronic has acquired to date? | As of May 2026, Medtronic has acquired 39 companies. |
| What was the largest acquisition by Medtronic? | $43B acquisition of Covidien on 15th June 2014 was the largest M&A Medtronic has done to date. |
| What companies Medtronic acquired? | Medtronic acquired Covidien, Mazor Robotics, Intersect ENT, HeartWare International, Affera, CathWorks, Scientia Vascular, NGC Medical SpA, Twelve, Smith & Nephew (gynecology unit), and 29 other companies. |
| In how many companies Medtronic has invested to date? | As of May 2026, Medtronic has invested in 25 companies. |
| What was the last Medtronic investment? | On 19th April 2026 Medtronic invested in Pulnovo Medical, participating in a $100M Series D round, alongside EQT, Gaorong Capital, HSG, Lilly Asia Ventures, OrbiMed, and Qiming Venture Partners. |
| In what companies Medtronic invested in? | Medtronic invested in Semma Therapeutics, Orchestra BioMed, Pulnovo Medical, CathWorks, Earlens, Scivita Medical Technology, FIRE1, Inspire Medical Systems, AEGEA Medical, Saluda Medical, Glooko, SetPoint Medical, Intersect ENT, BioProtect, Avation Medical, AcuFocus, PowerVision, Triple Jump Medical, CardioInsight Technologies, Brainsgate, and 5 other companies. |
See public comps similar to Medtronic
Lists including Medtronic
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




